Pharmaceuticals
Positive Outcome from a Phase Ib Study in Australia Treating Patients with Androgenic Alopecia
SHANGHAI, Jan. 14, 2024 /PRNewswire/ -- Hope Medicine Inc. ('HopeMed'), a clinical-stage innovative biopharmaceutical company, announced recently that the company has completed a Phase Ib study, "An Open-Label Study, to Evaluate Safety, Tolerability, and Efficacy in Male and Female with Androgene...
2024-01-15 08:08
3841
Qilian International Holding Group Receives 180-day Extension from Nasdaq to Meet Minimum Bid Price Rule
JIUQUAN, China, Jan. 12, 2024 /PRNewswire/ -- Qilian International Holding
Group Limited (NASDAQ: QLI
2024-01-12 20:30
6404
ClinChoice Acquires CSI, Expanding its Global Footprint into Southeast Asia
SHANGHAI, PHILADELPHIA and SINGAPORE, Jan. 11, 2024 /PRNewswire/ -- ClinChoice, a leading global Contract Research Organization (CRO), today announced expanding its global footprint with the acquisition of CSI Medical Research (CSI). CSI is a regional clinical CRO with professional staff and part...
2024-01-12 11:00
4347
GenFleet Therapeutics Announces GFH009 Granted with FDA Fast Track, Orphan Drug Designations for Treating R/R Peripheral T-cell Lymphomas and Acute Myeloid Leukemia
SHANGHAI, Jan. 11, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company developing cutting-edge therapies in oncology and immunology, announced that U.S. Food and Drug Administration (FDA) has recently granted another two designations for SLS009 (GFH009). GFH009 (hig...
2024-01-11 19:00
2524
CEO of Kelun-Biotech Dr. Micheal Ge delivered a presentation on The 42nd JPM Annual Healthcare Conference
SAN FRANCISCO, Jan. 11, 2024 /PRNewswire/ -- The 42nd J.P. Morgan Annual Healthcare Conference（"JPMHC"）2024 is taking place onJanuary 8-11 at San Fracisco,USA, members of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK, Kelun-Biotech) senior management team participated in the conferen...
2024-01-11 17:55
2730
SyntheticGestalt and Enamine to Collaborate on the Creation of AI-Based Model to Facilitate Drug Discovery
SyntheticGestalt will develop a pre-trained AI model to discover synthesizable drug-like hit candidates. This model will utilize 38 billion compounds from Enamine REAL database as a dataset for pre-training. TOKYO and KYIV, Ukraine, Jan. 11, 2024 /PRNewswire/ -- SyntheticGestalt, a research and ...
2024-01-11 16:00
2361
Ascentage Pharma Presented at 42nd Annual J.P. Morgan Healthcare Conference
SUZHOU, China and ROCKVILLE, Md., Jan. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a commercial stage global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that Dr.Dajun Yang, the company's ...
2024-01-11 11:53
5557
New Chinese medicine drug developed by HKBU for myofibrillar myopathy granted orphan drug designation by FDA
HONG KONG, Jan. 10, 2024 /PRNewswire/ -- The Centre for Chinese Herbal Medicine
Drug Development
2024-01-10 16:50
2802
LOTTE BIOLOGICS Announces Songdo Bio Plant Development Plan at JPM Healthcare Conference 2024
* Richard Lee, CEO of LOTTE BIOLOGICS, delivers a keynote speech at the JPM Healthcare Conference for the second consecutive year * Unveils company's bio plant development plan in Songdo to meet clients' needs SEOUL, South Korea, Jan. 9, 2024 /PRNewswire/ -- LOTTE BIOLOGICS (CEO Richard Lee) ...
2024-01-10 08:55
4342
Enhancing Leadership in Gynecology, Asieris Pharmaceuticals Appoints Sophia Cao to Lead the Newly-Established Women's Health Business Unit, Accelerating Strategic Expansion
SHANGHAI, Jan. 8, 2024 /PRNewswire/ -- Asieris Pharmaceuticals (Stock code ：688176.SH) has announced its set-up of the Women's Health Business Unit for commercialization. This strategic move is designed to enhance the company's focus on genitourinary diseases and strengthen its position in women'...
2024-01-09 12:25
2528
Abbisko Therapeutic announces that EMA has granted orphan drug designation for its CSF-1R inhibitor Pimicotinib （ABSK021）
SHANGHAI, Jan. 8, 2024 /PRNewswire/ -- On January 9, 2024 (Beijing Time), Abbisko Therapeutics (HKEX code: 02256) announced that its investigational innovative CSF-1R inhibitor pimicotinib（ABSK021） has been granted orphan drug designation（ODD） by the European Medicines Agency (EMA) for the treatm...
2024-01-09 08:30
2470
Akeso to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Share Its Corporate & Innovative Clinical Development Roadmap
HONG KONG, Jan. 8, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso," "we," or the "Company") today announced thatMichelle Xia, Ph.D, the founder, chairwoman, president, and CEO of Akeso, will deliver a keynote speech focusing on the Company's achievements in the development of new bispecific a...
2024-01-08 21:38
2758
Biosion's Partner OBI Pharma Announces FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992 (TROP2 ADC)
- First clinical trial to evaluate the safety and efficacy of OBI-992 (a.k.a BSI-992), a novel antibody drug conjugate (ADC) targeting TROP2 - Dosing of first patient in the Phase 1/2 clinical trial expected in early 2024 NEWARK, Del. and NANJING, China, Jan. 8, 2024 /PRNewswire/ -- The Partner ...
2024-01-08 19:35
4144
Caliway Announces FDA Acceptance of CBL-514 IND Application for Placebo-Controlled Phase 2 Study to treat Dercum's Disease
NEW TAIPEI CITY, Jan. 8, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announced that the United States Food and Drug Administration (U.S. FDA) has accepted the CBL-514 Investigational New Drug (IND) application of CBL-0202 DD Phase 2 Study to treat Dercum's Disease. Dercum's disease...
2024-01-08 13:25
3293
Shanghai Argo Announces Multi-Program RNAi Licenses and Strategic Collaborations with Novartis
- Argo will receive upfront payments of $185 million from Novartis and is eligible to receive potential option and milestone payments as well as tiered royalties on commercial sales. - Novartis will receive an ex-Greater China exclusive license for a Phase 1/2a stage cardiovascular asset, a worl...
2024-01-08 07:00
2209
Supplemental New Drug Application for Akeso's Cadonilimab (PD-1/CTLA-4) Accepted by NMPA for First-line Treatment of Gastric Cancer
HONG KONG, Jan. 5, 2024 /PRNewswire/ -- Akeso (9926.HK) announced the China National Medical Products Administration (NMPA) has accepted the supplemental new drug application (sNDA) of cadonilimab(开坦尼®, PD-1/CTLA-4 bispecific antibody, AK104) in combination with capecitabine plus oxaliplatin (XEL...
2024-01-05 21:00
6981
SanReno Therapeutics Announces Acquisition by Novartis in Pivotal Transaction to Bring Forward Transformative Therapeutics in Kidney Disease
* Novartis to acquire SanReno's product pipeline and capabilities, including the exclusive rights forGreater China and Singapore * Transaction reflects the Novartis commitment to the Chinese market and complements existing pipeline in renal diseases. SHANGHAI, Jan. 5, 2024 /PRNewswire/ -- San...
2024-01-05 16:00
3498
OnCusp Therapeutics Raises Oversubscribed $100 Million Series A Financing to Advance Portfolio of Assets for Cancer Patients
* Financing led by Novo Holdings, OrbiMed, and F-Prime Capital, with participation by new and current investors * Proceeds to advance CUSP06, the company's antibody drug conjugate (ADC) targetingCDH6, to clinical proof-of-concept NEW YORK, Jan. 4, 2024 /PRNewswire/ -- OnCusp Therapeutics, Inc...
2024-01-04 21:11
2395
Jiangsu Vcare Files NDA for Vicagrel Capsules with US FDA
NANJING, China, Jan. 4, 2024 /PRNewswire/ -- On December 28, 2023, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) successfully submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Vicagrel capsule, which is indicated to treat a range of thrombotic cardiova...
2024-01-04 21:05
3134
GenScript, GenScript ProBio, and Legend Biotech Will Attend the 42nd JPM Healthcare Conference, Advancing Innovation and Development in the Healthcare Sector
NANJING, China, Jan. 4, 2024 /PRNewswire/ -- GenScript Biotech, a global leader in life science research and manufacturing services, along with its subsidiaries GenScript ProBio and Legend Biotech, will be attending the 42nd JPM Healthcare Conference held inSan Francisco, California, USA, from Ja...
2024-01-04 17:37
5532
Week's Top Stories
Most Reposted
Agoda Begins Limited Public Beta of New AI Assistant That Turns Travel Ideas into Bookable Trips
[Picked up by 287 media titles]
2026-09-15 11:00
Sovereign Investment Institutions Launch China-ASEAN Joint Investment Council
[Picked up by 267 media titles]
2026-09-16 09:09
Novo Holdings invests in ForYou Medical to support global growth in advanced wound care manufacturing
[Picked up by 264 media titles]
2026-09-10 15:00CLP Power Hosts AESIEAP CEO Conference 2026 in Hong Kong
[Picked up by 260 media titles]
2026-09-15 19:07
New ASEAN Study Reveals Businesses Are Rethinking Hiring and Investment as Growth Priorities Shift
[Picked up by 260 media titles]
2026-09-10 07:45
Most Read
ALLSWIFIT Introduces ActiveRise+, a Stable Carbon-Plate Running Shoe Built to Help Everyday Runners Train Smarter and Run Stronger
2026-09-11 21:00
12482
Cheetah Mobile Announces Second Quarter 2026 Unaudited Consolidated Financial Results
2026-09-11 10:36
7916